Clinical observation of beprostol sodium combined with milrinone in treatment of pulmonary hypertension associated with left heart disease.

  AIM  To observe the clinical efficacy of beprostol combined with milrinone in the treatment of left heart disease-associated pulmonary hypertension (PH-LHD).

  METHODS  From January 2019 to January 2021, 184 PH-LHD patients were randomly divided into 4 groups with 46 patients in each group. The routine treatment group was given symptomatic treatment such as oxygen inhalation, anticoagulation, diuresis and cardiotonic therapy; the beprostol sodium group was treated with oral beprostol sodium on the basis of routine treatment; the milrinone group was treated with milrinone intravenously on the basis of routine treatment; and the combination group was treated with peprostatin sodium and milrinone at the same time on the basis of routine treatment. The changes of brain natriuretic peptide (BNP), arterial partial pressure of oxygen (PO₂), pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF), 6-minute walking distance (6MWD), WHO pulmonary hypertension function grade (WHO-FC) and side effects were observed before and after treatment in the four groups.

  RESULTS  After 72 hours’ treatment, BNP of the four groups was significantly lower than that before treatment (P<0.05), BNP of milrinone group and combination group was significantly lower than that of the other two groups (P<0.05, P<0.01), HR was significantly higher than that of the other two groups (P<0.01), and the hospitalization days of combination group were significantly less than those of the other three groups (P<0.05). After 12 weeks’ treatment, BNP, 6MWD, PO2, PASP, LVEF and WHO-FC in combined group were significantly improved (P<0.01) as compared with those in routine group (P<0.05), the level of LVEF in combined group was significantly higher than that in beprostol sodium group (P<0.05) and the levels of 6MWD, PO₂ and PASP in combined group were significantly better than those in milrinone group (P<0.05). There was no significant difference in the incidence of adverse reactions among the four groups.

  CONCLUSION  Beprostol sodium combined with milrinone is more effective in the treatment of PH-LHD than routine treatment or single use of beprostol sodium or milrinone.